Compare MBBC & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | RNXT |
|---|---|---|
| Founded | 1902 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 36.4M |
| IPO Year | N/A | 2021 |
| Metric | MBBC | RNXT |
|---|---|---|
| Price | $11.64 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 7.4K | ★ 214.1K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $7,299,708.00 | $928,000.00 |
| Revenue This Year | N/A | $2,795.35 |
| Revenue Next Year | N/A | $272.69 |
| P/E Ratio | $101.88 | ★ N/A |
| Revenue Growth | ★ 7.77 | N/A |
| 52 Week Low | $8.74 | $0.70 |
| 52 Week High | $12.89 | $1.69 |
| Indicator | MBBC | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 57.56 | 44.91 |
| Support Level | $11.21 | $0.83 |
| Resistance Level | $11.99 | $1.00 |
| Average True Range (ATR) | 0.29 | 0.06 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 63.92 | 36.53 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.